Sphingosine-1-phosphate and its receptors: Structure, signaling, and influence

Annual Review of Biochemistry

Volumn 82, Issue , 2013, Pages 637-662

  Rosen, Hugh ^a   Stevens, Raymond C ^a   Hanson, Michael ^b   Roberts, Edward ^a   Oldstone, Michael B A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Receptos   (United States)

Author keywords

Chemical biology; GPCR; Receptor crystal structure; Sphingosine 1 phosphate

Indexed keywords

G PROTEIN COUPLED RECEPTOR; RHODOPSIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ALLOSTERISM; CRYSTAL STRUCTURE; HUMAN; IN VIVO STUDY; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; LIGANDS; MICE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION;

MUS;

EID: 84878906549     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-062411-130916     Document Type: Review

References (151)

1. Broder S, Venter JC. 2000. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Annu. Rev. Pharmacol. Toxicol. 40:97-132
2. Gilman AG. 1987. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56:615-49
3. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. 2009. Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 78:743-68
4. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-49
5. Allende ML, Proia RL. 2002. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim. Biophys. Acta 1582:222-27
6. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, et al. 2000. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Investig. 106:951-61
7. Hla T, Maciag T. 1990. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J. Biol. Chem. 265:9308-13
8. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, et al. 2010. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9:883-97
9. Cyster JG, Schwab SR. 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30:69-94
10. Maceyka M, Harikumar KB, Milstien S, Spiegel S. 2012. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 22:50-60
11. Spiegel S, Milstien S. 2011. The outs and the ins of sphingosine-1- phosphate in immunity. Nat. Rev. Immunol. 11:403-15
12. Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG. 2011. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br. J. Pharmacol. 163:1329-43
13. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. 2005. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25:11113-21
14. Osborne N, Brand-Arzamendi K, Ober EA, Jin SW, Verkade H, et al. 2008. The spinster homolog, two of hearts, is required for sphingosine 1-phosphate signaling in zebrafish. Curr. Biol. 18:1882-88
15. Fyrst H, Saba JD. 2010. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat. Chem. Biol. 6:489-97
16. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, et al. 2006. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114:1403-9
17. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, et al. 2004. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279:13839-48
18. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, et al. 2004. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. 309:758-68
19. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, et al. 2006. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2:434-41
20. Mutoh T, Rivera R, Chun J. 2012. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 165:829-44
21. Kono M, Belyantseva IA, Skoura A, Frolenkov GI, Starost MF, et al. 2007. Deafness and stria vascularis defects in S1P2 receptor-null mice. J. Biol. Chem. 282:10690-96
22. Sakurai A, Nakano Y, Koganezawa M, Yamamoto D. 2010. Phenotypic interactions of spinster with the genes encoding proteins for cell death control in Drosophila melanogaster. Arch. Insect Biochem. Physiol. 73:119-27
23. Legangneux E, Gardin A, Johns D. 2013. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br. J. Clin. Pharmacol. 75:831-41
24. Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, et al. 2010. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J. Exp. Med. 207:17-27
25. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, et al. 2007. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316:295-98
26. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. 2005. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309:1735-39
27. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, et al. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355-60
28. Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. 2003. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proc. Natl. Acad. Sci. USA 100:10907-12
29. Foss FW Jr, Snyder AH, Davis MD, Rouse M, Okusa MD, et al. 2007. Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg. Med. Chem. 15:663-77
30. Thangada S, Khanna KM, Blaho VA, Oo ML, ImD-S, et al. 2010. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J. Exp. Med. 207:1475-83
31. Tarrasn G, Auli, Mustafa S, Dolgachev V, Domènech MT, et al. 2011. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int. Immunopharmacol. 11:1773-79
32. Fujii Y, Hirayama T, Ohtake H, Ono N, Inoue T, et al. 2012. Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities. J. Immunol. 188:206-15
33. Quancard J, Bollbuck B, Janser P, Angst D, Berst F, et al. 2012. A potent and selective S1P1 antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem. Biol. 19:1142-51
34. Cahalan SM, Gonzalez-Cabrera PJ, Nguyen N, Guerrero M, George Cisar EA, et al. 2012. S1P1 receptor upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P1 antagonist. Mol. Pharmacol. 83:316-21
35. Cahalan SM, Gonzalez-Cabrera PJ, Sarkisyan G, Nguyen N, Schaeffer MT, et al. 2011. Actions of a picomolar short-acting S1P agonist in S1P1-eGFP knock-in mice. Nat. Chem. Biol. 7:254-56
36. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. 2008. S1P1 receptor signaling overrides retention mediated by Gαi-coupled receptors to promote T cell egress. Immunity 28:122-33
37. Arnon TI, Xu Y, Lo C, Pham T, An J, et al. 2011. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333:1898-903
38. Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, et al. 2011. Engagement of S1P-degradative mechanisms leads to vascular leak in mice. J. Clin. Investig. 121:2290-300
39. Allende ML, Dreier JL, Mandala S, Proia RL. 2004. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J. Biol. Chem. 279:15396-401
40. Hla T, Brinkmann V. 2011. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology 76:S3-8
41. Gonzalez-Cabrera PJ, Cahalan SM, Nguyen N, Sarkisyan G, Leaf NB, et al. 2011. S1P1 receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol. Pharmacol. 81:166-74
42. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, et al. 2008. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol. Pharmacol. 74:1308-18
43. Gonzalez-Cabrera PJ, Hla T, Rosen H. 2007. Mapping pathways downstream of sphingosine 1- phosphate subtype 1 by differential chemical perturbation and proteomics. J. Biol. Chem. 282:7254-64
44. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, et al. 2005. S1P1-selective in vivoactive agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 12:703-15
45. Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, et al. 2011. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl. Acad. Sci. USA 108:12018-23
46. Walsh KB, Teijaro JR, Rosen H, Oldstone MB. 2011. Quelling the storm: utilization of sphingosine- 1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol. Res. 51:15-25
47. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, et al. 2011. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:980-91
48. Walsh KB, Marsolais D, Welch MJ, Rosen H, Oldstone MBA. 2010. Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection. Virology 397:260-69
49. Marsolais D, Hahm B, Walsh KB, Edelmann KH, McGavern D, et al. 2009. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc. Natl. Acad. Sci. USA 106:1560-65
50. Marsolais D, Hahm B, Edelmann KH, Walsh KB, Guerrero M, et al. 2008. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol. Pharmacol. 74:896-903
51. Radue EW, OConnor P, Polman CH, Hohlfeld R, Calabresi P, et al. 2012. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch. Neurol. 69:1259-69
52. Devonshire V, Havrdova E, Radue EW, OConnor P, Zhang-Auberson L, et al. 2012. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 11:420-28
53. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, et al. 2011. Comparison of fingolimod with interferonβ-1a in relapsing-remitting multiple sclerosis: a randomised extension of theTRANSFORMS study. Lancet Neurol. 10:520-29
54. Kappos L, Radue EW, OConnor P, Polman C, Hohlfeld R, et al. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362:387-401
55. Kappos L, Antel J, Comi G, Montalban X, OConnor P, et al. 2006. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355:1124-40
56. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. 2012. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76:16-32
57. Darwish I, Mubareka S, Liles WC. 2011. Immunomodulatory therapy for severe influenza. Expert Rev. Anti-Infect. Ther. 9:807-22
58. Cheng XW, Lu J, Wu CL, Yi LN, Xie X, et al. 2011. Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm. Respir. Physiol. Neurobiol. 175:185-87
59. Wang S, Le TQ, Kurihara N, Chida J, Cisse Y, et al. 2010. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J. Infect. Dis. 202:991-1001
60. Iwasaki A, Medzhitov R. 2011. A new shield for a cytokine storm. Cell 146:861-62
61. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, et al. 2011. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. USA 108:751-56
62. Marsolais D, Rosen H. 2009. Chemical modulators of sphingosine-1- phosphate receptors as barrieroriented therapeutic molecules. Nat. Rev. Drug Discov. 8:297-307
63. Katritch V, Cherezov V, Stevens RC. 2012. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33:17-27
64. Wu HX, Wacker D, Mileni M, Katritch V, Han GW, et al. 2012. Structure of the human ω-opioid receptor in complex with JDTic. Nature 485:327-32
65. Thompson AA, Liu W, Chun E, Katritch V, Wu HX, et al. 2012. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485:395-99
66. Hanson M, Roth C, Jo E, Griffith M, Scott F, et al. 2012. Crystal structure of a lipid G-protein coupled receptor. Science 335:851-55
67. Guerrero M, Urbano M, Zhao J, Crisp M, Chase P, et al. 2012. Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists. Bioorg. Med. Chem. Lett. 22:537-42
68. Urbano M, Guerrero M, Zhao J, Velaparthi S, Schaeffer MT, et al. 2011. SAR analysis of innovative selective small molecule antagonists of sphingosine-1-phosphate 4 (S1P4) receptor. Bioorg. Med. Chem. Lett. 21:5470-74
69. Urbano M, Guerrero M, Velaparthi S, Crisp M, Chase P, et al. 2011. Discovery, synthesis and SAR analysis of novel selective small molecule S1P4-R agonists based on a (2Z, 5Z)-5-((pyrrol-3-yl)methylene)- 3-alkyl-2-(alkylimino) thiazolidin-4-one chemotype. Bioorg. Med. Chem. Lett. 21:6739-45
70. Guerrero M, Urbano M, Velaparthi S, Zhao J, Schaeffer MT, et al. 2011. Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists. Bioorg. Med. Chem. Lett. 21:3632-36
71. Schürer SC, Brown SJ, Gonzalez-Cabrera PJ, Schaeffer MT, Chapman J, et al. 2008. Ligand-binding pocket shape differences between sphingosine 1-phosphate (S1P) receptors S1P1 and S1P3 determine efficiency of chemical probe identification by ultrahigh-throughput screening. ACS Chem. Biol. 3:486-98
72. Topiol S, Sabio M. 2009. X-ray structure breakthroughs in the GPCR transmembrane region. Biochem. Pharmacol. 78:11-20
73. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, et al. 2007. GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318:1266-73
74. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et al. 2007. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318:1258-65
75. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-45
76. Okada T, Le Trong I, Fox BA, Behnke CA, Stenkamp RE, Palczewski K. 2000. X-ray diffraction analysis of three-dimensional crystals of bovine rhodopsin obtained from mixedmicelles. J. Struct. Biol. 130:73-80
77. Deflorian F, Kumar TS, Phan K, Gao ZG, Xu F, et al. 2012. Evaluation ofmolecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A2A adenosine receptor. J. Med. Chem. 55:538-52
78. Chun E, Thompson Aaron A, Liu W, Roth Christopher B, Griffith Mark T, et al. 2012. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20:967-76
79. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, et al. 2012. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-36
80. Pydi SP, Bhullar RP, Chelikani P. 2012. Constitutively active mutant gives novel insights into the mechanism of bitter taste receptor activation. J. Neurochem. 122:537-44
81. Schneider EH, Schnell D, Strasser A, Dove S, Seifert R. 2010. Impact of the DRY motif and the missing ionic lock on constitutive activity and G-protein coupling of the human histamine H4 receptor. J. Pharmacol. Exp. Ther. 333:382-92
82. Ohno Y, Ito A, Ogata R, Hiraga Y, Igarashi Y, Kihara A. 2009. Palmitoylation of the sphingosine 1- phosphate receptor S1P1 is involved in its signaling functions and internalization. Genes Cells 14:911-23
83. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al. 2007. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450:383-87
84. Cherezov V, Abola E, Stevens RC. 2010. Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets. Methods Mol. Biol. 654:141-68
85. Xu F, Liu W, Hanson MA, Stevens RC, Cherezov V. 2011. Development of an automated high throughput LCP-FRAP assay to guide membrane protein crystallization in lipid mesophases. Cryst. Growth Des. 11:1193-201
86. Fujiwara Y, Osborne DA, Walker MD, Wang DA, Bautista DA, et al. 2007. Identification of the hydrophobic ligand binding pocket of the S1P1 receptor. J. Biol. Chem. 282:2374-85
87. Fujiwara Y, Sardar V, Tokumura A, Baker D, Murakami-Murofushi K, et al. 2005. Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J. Biol. Chem. 280:35038-50
88. Inagaki Y, Pham TT, Fujiwara Y, Kohno T, Osborne DA, et al. 2005. Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors. Biochem. J. 389:187-95
89. Wang DA, Lorincz Z, Bautista DL, Liliom K, Tigyi G, Parrill AL. 2001. A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J. Biol. Chem. 276:49213-20
90. Parrill AL, Wang D, Bautista DL, Van Brocklyn JR, Lorincz Z, et al. 2000. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J. Biol. Chem. 275:39379-84
91. Parrill AL, Baker DL, Wang DA, Fischer DJ, Bautista DL, et al. 2000. Structural features of EDG1 receptor-ligand complexes revealed by computational modeling and mutagenesis. Ann. N. Y. Acad. Sci. 905:330-39
92. Kufareva I, Rueda M, Katritch V, Stevens RC, Abagyan R. 2011. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 19:1108-26
93. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, et al. 2010. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066-71
94. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, et al. 2010. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330:1091-95
95. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, et al. 2011. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477:549-55
96. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, et al. 2011. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469:175-80
97. Kohno T, Igarashi Y. 2004. Roles for N-glycosylation in the dynamics of Edg-1/S1P1 in sphingosine 1-phosphate-stimulated cells. Glycoconj. J. 21:497-501
98. Kohno T, Igarashi Y. 2003. Truncation of the N-terminal ectodomain has implications in the Nglycosylation and transport to the cell surface of Edg-1/S1P1 receptor. J. Biochem. 134:667-73
99. Granier S, Kobilka B. 2012. A new era of GPCR structural and chemical biology. Nat. Chem. Biol. 8:670-73
100. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. 2009. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol. 5:428-34
101. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, et al. 2007. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282:9082-89
102. Murata N, Sato K, Kon J, Tomura H, Yanagita M, et al. 2000. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352:809-15
103. Sardar VM, Bautista DL, Fischer DJ, Yokoyama K, Nusser N, et al. 2002. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim. Biophys. Acta 1582:309-17
104. Smith SO. 2012. Insights into the activation mechanism of the visual receptor rhodopsin. Biochem. Soc. Trans. 40:389-93
105. Kontoyianni M, Liu Z. 2012. Structure-based design in the GPCR target space. Curr. Med. Chem. 19:544-56
106. Ahuja S, Crocker E, Eilers M, Hornak V, Hirshfeld A, et al. 2009. Location of the retinal chromophore in the activated state of rhodopsin. J. Biol. Chem. 284:10190-201
107. Palczewski K. 2006. G protein-coupled receptor rhodopsin. Annu. Rev. Biochem. 75:743-67
108. Deng Q, Clemas JA, Chrebet G, Fischer P, Hale JJ, et al. 2007. Identification of Leu276 of the S1P1 receptor and Phe263 of the S1P3 receptor in interaction with receptor specific agonists by molecular modeling, site-directed mutagenesis, and affinity studies. Mol. Pharmacol. 71:724-35
109. Jo E, Bhhatarai B, Repetto E, Guerrero M, Riley S, et al. 2012. Novel selective allosteric and bitopic ligands for the S1P3 receptor. ACS Chem. Biol. 7:1975-83
110. Bhattacharya S, Hall SE, Vaidehi N. 2008. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors. J. Mol. Biol. 382:539-55
111. Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S. 2012. Action of molecular switches in GPCRs-theoretical and experimental studies. Curr. Med. Chem. 19:1090-109
112. Shan J, Khelashvili G, Mondal S, Mehler EL, Weinstein H. 2012. Ligand-dependent conformations and dynamics of the serotonin 5-HT2A receptor determine its activation and membrane-driven oligomerization properties. PLoS Comput. Biol. 8:e1002473
113. Tiburu EK, Tyukhtenko S, Zhou H, Janero DR, Struppe J, Makriyannis A. 2011. Human cannabinoid 1 GPCRC-terminal domain interactswith bilayer phospholipids tomodulate the structure of its membrane environment. AAPS J. 13:92-98
114. Borroto-Escuela DO, Romero-Fernandez W, Garc-Negredo G, Correia PA, Garriga P, et al. 2011. Dissecting the conserved NPxxY motif of the M3 muscarinic acetylcholine receptor: critical role of Asp-7. 49 for receptor signaling and multiprotein complex formation. Cell. Physiol. Biochem. 28:1009-22
115. Foss FW Jr, Clemens JJ, Davis MD, Snyder AH, Zigler MA, et al. 2005. Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors. Bioorg. Med. Chem. Lett. 15:4470-74
116. Awad AS, Ye H, Huang LP, Li L, Foss FW, et al. 2006. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Ren. Physiol. 290:F1516-F24
117. Davis MD, Clemens JJ, Macdonald TL, Lynch KR. 2005. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280:9833-41
118. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, et al. 2011. Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-27
119. Dor AS, Robertson N, Errey JC, Ng I, Hollenstein K, et al. 2011. Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19:1283-93
120. Beierlein FR, Othersen OG, Lanig H, Schneider S, Clark T. 2006. Simulating FRET from tryptophan: Is the rotamer model correct? J. Am. Chem. Soc. 128:5142-52
121. Smith SO. 2010. Structure and activation of the visual pigment rhodopsin. Annu. Rev. Biophys. 39:309-28
122. Holst B, Nygaard R, Valentin-Hansen L, Bach A, Engelstoft MS, et al. 2010. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J. Biol. Chem. 285:3973-85
123. Valant C, Robert Lane J, Sexton PM, Christopoulos A. 2012. The best of both worlds? Bitopic orthosteric/ allosteric ligands of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52:153-78
124. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, et al. 2012. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J. Med. Chem. 55:1445-64
125. Yin S, Zamorano R, Conn PJ, Niswender CM. 2013. Functional selectivity induced by mGlu4 receptor positive allosteric modulation and concomitant activation of Gq coupled receptors. Neuropharmacology 66:122-32
126. Mueller R, Dawson ES, Niswender CM, Butkiewicz M, Hopkins CR, et al. 2012. Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. J. Mol. Model. 18:4437-46
127. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, et al. 2012. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinsons disease. J. Pharmacol. Exp. Ther. 340:404-21
128. Wood MR, Hopkins CR, Brogan JT, Conn PJ, Lindsley CW. 2011. Molecular switches on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 50:2403-10
129. Williams R, Manka JT, Rodriguez AL, Vinson PN, Niswender CM, et al. 2011. Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Bioorg. Med. Chem. Lett. 21:1350-53
130. Sheffler DJ, Gregory KJ, Rook JM, Conn PJ. 2011. Allosteric modulation of metabotropic glutamate receptors. Adv. Pharmacol. 62:37-77
131. Reid PR, Bridges TM, Sheffler DJ, Cho HP, Lewis LM, et al. 2011. Discovery and optimization of a novel, selective and brain penetrantM1 positive allosteric modulator (PAM): the development ofML169, an MLPCN probe. Bioorg. Med. Chem. Lett. 21:2697-701
132. Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, et al. 2010. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system. ACS Chem. Neurosci. 1:104-21
133. Digby GJ, Shirey JK, Conn PJ. 2010. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol. Biosyst. 6:1345-54
134. Digby GJ, Conn PJ, Lindsley CW. 2010. Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. Curr. Opin. Drug Discov. Dev. 13:587-94
135. Davis AA, Heilman CJ, Brady AE, Miller NR, Fuerstenau-Sharp M, et al. 2010. Differential effects of allosteric M1 muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation. ACS Chem. Neurosci. 1:542-51
136. Bridges TM, Phillip Kennedy J, Noetzel MJ, Breininger ML, Gentry PR, et al. 2010. Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAM. Bioorg. Med. Chem. Lett. 20:1972-75
137. Bridges TM, Kennedy JP, Hopkins CR, Conn PJ, Lindsley CW. 2010. Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. Bioorg. Med. Chem. Lett. 20:5617-22
138. Bridges TM, Kennedy JP, Cho HP, Breininger ML, Gentry PR, et al. 2010. Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: development of the first highly selective M5 PAM. Bioorg. Med. Chem. Lett. 20:558-62
139. Valentine WJ, Godwin VI, Osborne DA, Liu J, Fujiwara Y, et al. 2011. FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2. J. Biol. Chem. 286:30513-25
140. Valentine WJ, Kiss GN, Liu J, Shuyu E, Gotoh M, et al. 2010. (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. Cell Signal. 22:1543-53
141. Waters CM, Long J, Gorshkova I, Fujiwara Y, Connell M, et al. 2005. Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J. 20:509-11
142. Canals M, Sexton PM, Christopoulos A. 2011. Allostery in GPCRs: MWC revisited. Trends Biochem. Sci. 36:663-72
143. Marsolais D, Yagi S, Kago T, Leaf N, Rosen H. 2011. Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs. Mol. Pharmacol. 79:61-68
144. Herr DR, Grillet N, Schwander M, Rivera R, Müller U, Chun J. 2007. Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J. Neurosci. 27:1474-78
145. Levkau B. 2008. Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness. Circ. Res. 103:231-33
146. Roviezzo F, Di Lorenzo A, Bucci M, Brancaleone V, Vellecco V, et al. 2007. Sphingosine-1- phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 36:757-62
147. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, et al. 2004. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 169:1245-51
148. McVerry BJ, Garcia JG. 2005. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal. 17:131-39
149. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. 2004. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am. J. Respir. Crit. Care Med. 170:987-93
150. Awad AS, Ye H, Huang L, Li L, Foss FW Jr, et al. 2006. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Ren. Physiol. 290:F1516- 24
151. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, et al. 2008. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 19:254-66